Evaluation of genetic risk factors for silent brain infarction

Stroke

Volumn 30, Issue 9, 1999, Pages 1881-1886

  Notsu, Yoshitomo ^a   Nabika, Toru ^a   Park, Hyun Young ^a   Masuda, Junichi ^a   Kobayashi, Shotai ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Amine oxidoreductases; Angiotensin converting enzymes; Apolipoproteins; Genetics; Lacunar infarction

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; RESTRICTION ENDONUCLEASE;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; WESTERN BLOTTING; WHITE MATTER;

EID: 0032829537     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.9.1881     Document Type: Article

References (48)

1. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28:1932-1939.
2. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-relatcd cerebral damage in the Austrian Stroke Prevention Study. J Neural Sei. 1997;152:15-21.
3. Van Zagten M, Boiten J, Kessels F, Lodder J. Significant progression of white matter lesions and small deep (lacunar) infarcts in patients with stroke. Arch Neurol. 1996;53:650-655.
4. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181.
5. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, Boers GJ, den Heijer M, Kluijtmans LA, Van der Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1996;10:111-113.
7. Markus HS, AH N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischémie cerebrovascular disease. Stroke. 1997; 28:1739-1743.
8. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Kitamura K, Yazaki Y. Methylenetetrahydrofolate reductase gene polymorphism and ischémie stroke in Japanese. Arterioscler Tliromb Vase Biol. 199S;18:1465-1469.
9. Sandholzer C, Mailman DM, Saha N, Sigurdsson G, Lackner A, Csaszar A, Boerwinkle E, Utermann G. Effects of apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
10. Boenvinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma Lp(a) concentrations. J Clin Invest. 1992;90:52-60.
11. Regerson F, Schlawe I, Paxinos G, Chai SY, McKinley MJ, Mendelsohn FAO. Localization of angiotensin converting enzyme by in vitro autoradiography in the rabbit brain. J Chem Neuroanat. 1995;8:227-243.
12. Hajdu MA, Heistad DD, Baumbach GL. Effects of amihypertensive therapy on mechanics of cerebral arterioles in rats. Hypertension. 1991; 17:308-316.
13. Van Swieten JC, Van Den Hout JHW, Van Ketel B A, Hijdra A, Wokke JHJ, Van Gijn J. Periventricular lesions in the white matter on magnetic resonance imaging in the elderly: a morphometric correlation with arteriolosclerosis and dilated perivascular spaces. Brain. 1991;! 14:761-774.
14. Mudd SH, Skovby F, Levy HL, Pettigrcw KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
15. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 1992;360:670-672.
16. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658.
17. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpcl PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation. 1997;96:2514-2519.
18. Takami S, Yamashita S, Kihara S, Ishigami M, Takemura K, Kume N, Kita T, Matsuzawa Y. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 1998;97:721-728.
19. Yano Y, Seishima M, Tokoro Y, Noma A. Stimulatory effects of lipoprotein(a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2. Biochim Biophys Acta. 1998;1393:26-34.
20. Longstreth WT, Bemick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neural. 1998;55: 1217-1225.
21. Watanabe Y, Ishigami T, Kawano Y, Umahara T, Nakamori A, Mizushima S, Hibi K, Kobayashi I, Tamura K, Ochiai H, Umemura S, Ishii M. Angiotensin-converting enzyme gene I/D polymorphism and carotid plaques in Japanese. Hypertension. 1997;30(pt 2):569-573.
22. Park H-Y, Nabika T, Notsu Y, Kobayashi S, Masuda J. Effects of the apolipoprotein(a) gene polymorphisms on the lipoprotein(a) concentration in Japanese. Clin Exp Pharmacol Physiol. 1999;26:304-308.
23. Abe A, Takashima M. Number of apolipoprotein(a) kringle IV repeats and mobility of isoforms in PAGE. Jpn J Clin Patliol. 1998;46:283-288.
24. Schriewer H, Assmann G, Sandkamp M, Schulte H. The relationship of lipoprotein(a) to risk factor of coronary heart disease: initial results of the prospective epidemiological study of company employees in Westfalia. J Clin Chem Clin Biochem. I984;22:591-596.
25. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of isché mie heart disease. N Engl J Med. 1995;332:706-711.
26. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke. 1993;24:965-969.
27. Pedro-Botet J, Senti M, Nogues X, Fubies-Prat J, Roquer J, D'Olhaberriague L, Olive J. Lipoprotein and apolipoprotein profile in men with ischémie stroke: role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 1992;23: 1556-1562.
28. Markus HS, Barley J, Lunt R, Bland M, Jeffery S, Carter ND, Brown MM. Angiotensin-converting enzyme gene deletion polymorphism: a new risk factor for lacunar stroke but not carotid atheroma. Stroke. 1995;26:1329-1333.
29. Catto A, Carter AM, Barrett JH, Stickland M, Bamford J, Davies JA, Grant PJ. Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Stroke. 1996;27:435-440.
30. Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J. 1998;135:S21-S30.
31. Kario K, Kanal N, Saito K, Nago N, Matsuo T, Shimada K. Ischémie stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation. 1996;93:1630-1633.
32. Liu J-N, Rung W, Harpel PC, Gurewich V. Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and endothelial cells. Biochemistry. 1998;37:3949-3954.
33. Syrovets T, Thillet J, Chapman MJ, Simmet T. Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood. 1997;90: 2027-2036.
34. Frazer KA, Narla G, Zhang JL, Rubin EM. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet. 1995;9:424-431.
35. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. J Clin Invest. 1992;89:1166-1171.
36. Maeda S, Abe A. Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.
37. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time: why epidemiological studies might fail. Arterioscler Thromb Vase Biol. 1996;16:1568-1572.
38. Woo J, Lau E, Lam CWK, Kay R, Teoh R, Wong HY, Prall WY, Kreel L, Nicholls MG. Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke. 1991;22:203-208.
39. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein(a) and ischémie cerebrovascular disease in young adults. Stroke. 1994;25:74-78.
40. Kario K, Matsuo T, Kobayashi H, Asada R, Matsuo M. "Silent" cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese. Arterioscler Tliromb Vase Biol. 1996;16:734-741.
41. Kang C, Durlach V, Soulat T, Foumier C, Angles-Cano E. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells. Arterioscler Thromb Vase Biol. 1997;17: 2036-2043.
42. Stehouwer CDA, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vase Biol. 1998;18:1895-1901.
43. Fisher CM. Lacunar strokes and infarcts: a review. Neurology. 1982;32: 871-876.
44. Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology. 1989;39:1246-1250.
45. You R, McNeil JJ, O'Malley HM, Davis SM, Donnan GA. Risk factors for lacunar infarction syndromes. Neurology. 1995;45:1483-1487.
46. Longstrelh WT, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neural. 1998;55: 1217-1225.
47. Khoury MJ, Beaty TU. Applications of the case-control method in genetic epidemiology. Epidemiol Rev. 1994;16:134-150.
48. Falk CT, Rubinstein P. Haplotype relative risk: an easy reliable way to construct a proper control sample for risk calculations. Ann Hum Genet. 1987;51:227-233.